Anti-HCV Treatment Regimens in India
For adults with chronic HCV infection in India, the recommended first-line treatment is sofosbuvir-based direct-acting antiviral (DAA) regimens, specifically sofosbuvir/velpatasvir for all genotypes or sofosbuvir/daclatasvir for genotype 3 (the most prevalent genotype in India), given for 12 weeks in non-cirrhotic patients.
Context for India
India has unique epidemiological characteristics that shape treatment recommendations:
- Genotype 3 predominates (approximately 72% of cases), followed by genotype 1 (22%) and genotype 4 (6%) 1
- Prevalence ranges from 0.5-1.5% nationally, with hotspots showing higher rates in northeast India, tribal populations, and parts of Punjab 2
- Cost and accessibility are critical considerations for treatment selection
Treatment Regimens by Genotype
Genotype 3 (Most Common in India)
Primary recommendation:
- Sofosbuvir (400 mg) + Daclatasvir (60 mg) daily for 12 weeks in treatment-naïve patients without cirrhosis 3, 1
- Alternative: Sofosbuvir (400 mg) + Velpatasvir (100 mg) daily for 12 weeks 3, 4
For patients with cirrhosis or treatment-experienced:
- Sofosbuvir + Daclatasvir (or Velpatasvir) for 24 weeks with ribavirin (1000-1200 mg based on weight) 3
- If NS5A Y93H resistance mutation is present, add ribavirin and extend to 24 weeks 3
Real-world Indian data: SVR12 rates of 97.3% for genotype 3 with sofosbuvir/daclatasvir regimens, including patients with cirrhosis 1. Another Indian study showed 91.9% SVR12 with dual-DAA regimens in genotype 3 patients 5.
Genotype 1
Primary recommendation:
- Sofosbuvir (400 mg) + Ledipasvir (90 mg) daily for 12 weeks 6, 1
- Alternative: Sofosbuvir + Daclatasvir for 12 weeks
For cirrhotic patients:
- Extend treatment to 24 weeks or add ribavirin for 12 weeks 6
Indian experience: 100% SVR12 achieved with sofosbuvir/ledipasvir in genotype 1 patients 1
Genotype 4
Primary recommendation:
- Sofosbuvir (400 mg) + Ledipasvir (90 mg) daily for 12 weeks 6
- Alternative: Paritaprevir/ritonavir/ombitasvir + ribavirin for 12 weeks 6
Indian data: 100% SVR12 with sofosbuvir-based regimens 1
Treatment Algorithm Based on Clinical Scenario
Step 1: Determine Genotype and Cirrhosis Status
- HCV RNA quantification and genotyping
- Assess for cirrhosis using transient elastography (FibroScan), APRI, or FIB-4 scores
- If cirrhosis present, determine Child-Pugh class
Step 2: Select Regimen
Non-cirrhotic, treatment-naïve:
- Genotype 3: Sofosbuvir/Daclatasvir × 12 weeks
- Genotype 1: Sofosbuvir/Ledipasvir × 12 weeks
- Genotype 4: Sofosbuvir/Ledipasvir × 12 weeks
Compensated cirrhosis (Child-Pugh A):
- Genotype 3: Sofosbuvir/Daclatasvir × 24 weeks + ribavirin
- Genotype 1: Sofosbuvir/Ledipasvir × 24 weeks OR 12 weeks + ribavirin
- Genotype 4: Sofosbuvir/Ledipasvir × 12 weeks + ribavirin
Decompensated cirrhosis (Child-Pugh B/C):
- Avoid protease inhibitors 3
- Sofosbuvir/Ledipasvir or Sofosbuvir/Velpatasvir or Sofosbuvir/Daclatasvir × 12-24 weeks with low-dose ribavirin (start 600 mg, titrate as tolerated) 3
Treatment-experienced (prior DAA failure):
- Consider sofosbuvir/velpatasvir/voxilaprevir (triple therapy) for 12 weeks 7
Critical Considerations
Ribavirin Dosing
- Weight-based: 1000 mg if <75 kg, 1200 mg if ≥75 kg 6, 3
- In decompensated cirrhosis: Start at 600 mg and increase as tolerated 3
- Monitor hemoglobin; avoid if baseline <10 g/dL 6
Common Pitfalls to Avoid
- Don't use sofosbuvir/ledipasvir for genotype 3 - ledipasvir has poor activity against genotype 3 3
- Don't use protease inhibitors in decompensated cirrhosis (Child-Pugh B/C) 3
- Don't undertreate cirrhotic patients - they require longer duration or ribavirin addition
- Don't skip NS5A resistance testing in genotype 3 treatment failures - Y93H mutation affects treatment selection 3
Monitoring
- HCV RNA at baseline, week 4 (optional for early virological response), end of treatment, and 12 weeks post-treatment (SVR12) 8
- Monitor for HBV reactivation if HBsAg positive 9
- Regular assessment of liver function and hemoglobin if on ribavirin
Special Populations
- HIV coinfection: Same regimens, but check for drug-drug interactions with antiretrovirals 4
- Post-transplant: Sofosbuvir/Ledipasvir + ribavirin × 12 weeks for genotype 1/4 in the allograft 6
- Renal impairment (CrCl >30 mL/min): No dose adjustment needed 6
The high SVR rates (>90%) achieved in Indian real-world studies 1, 5, 10 demonstrate that these sofosbuvir-based regimens are highly effective and well-tolerated in the Indian population across all genotypes and disease stages.